Quantitative changes in retinal pigment epithelial detachments as a predictor for retreatment with anti-VEGF therapy

Retina

Volumn 33, Issue 3, 2013, Pages 459-466

  Penha, Fernando M ^a   Gregori, Giovanni ^a   Garcia Filho, Carlos Alexandre De Amorim ^a   Yehoshua, Zohar ^a   Feuer, William J ^a   Rosenfeld, Philip J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

aflibercept; age related macular degeneration; anti VEGF; bevacizumab; optical coherence tomography; pigment epithelium detachment; ranibizumab; spectral domain

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

A SCAN; ADULT; AGED; ALGORITHM; ARTICLE; B SCAN; DIAGNOSTIC IMAGING EQUIPMENT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; QUALITATIVE ANALYSIS; RETINA DETACHMENT; RETINA MACULA LUTEA; RETREATMENT; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ALGORITHMS; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MALE; RETINAL DETACHMENT; RETINAL PIGMENT EPITHELIUM; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 84874949338     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31827d2657     Document Type: Article

References (12)

1. Gass JD. Pathogenesis of tears of the retinal pigment epithelium. Br J Ophthalmol 1984;68:513-519
2. Zayit-Soudry S, Moroz I, Loewenstein A. Retinal pigment epithelial detachment. Surv Ophthalmol 2007;52:227-243
3. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials - TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999; 117:1329-1345
4. Barbazetto I, Burdan A, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: Fluorescein angiographic guidelines for evaluation and treatment - TAP and VIP report No. 2. Arch Ophthalmol 2003; 121:1253-1268
5. Hee MR, Baumal CR, Puliafito CA, et al. Optical coherence tomography of age-related macular degeneration and choroidal neovascularization. Ophthalmology 1996;103:1260-1270
6. Coscas F, Coscas G, Souied E, et al. Optical coherence tomography identification of occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2007;144: 592-599
7. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-1431
8. Martin DF, Maguire MG, Ying GS, et al CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908
9. Gregori G, Wang F, Rosenfeld PJ, et al. Spectral domain optical coherence tomography imaging of drusen in non-exudative age-related macular degeneration. Ophthalmology 2011;118: 1373-1379
10. Yehoshua Z, Wang F, Rosenfeld PJ, et al. Natural history of drusen morphology in age-related macular degeneration using spectral domain optical coherence tomography. Ophthalmology 2011;118:2434-2441
11. Penha FM, Rosenfeld PJ, Gregori G, et al. Quantitative imaging of retinal pigment epithelial detachments using spectraldomain optical coherence tomography. Am J Ophthalmol 2012;153:515-523
12. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular agerelated macular degeneration: Year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.e1